Dannex Ayrton Starwin (XGHA:DASPHARMA) Current Deferred Revenue: GHS0.00 Mil (As of . 20)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XGHA:DASPHARMA Dannex Ayrton Starwin PLC XGHA:DASPHARMA
3 GF Score
Price GHS1.64
! 1 Warning Sign
View Full Analysis

What is Dannex Ayrton Starwin Current Deferred Revenue?

Dannex Ayrton Starwin XGHA:DASPHARMA -9.89% 3 Current Deferred Revenue is GHS0.00 Mil as of . 20. GuruFocus rates XGHA:DASPHARMA with a GF Score™ of 3/100. The stock has 1 warning sign investors should review.

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

Dannex Ayrton Starwin's current deferred revenue for the quarter that ended in . 20 was GHS0.00 Mil.

Dannex Ayrton Starwin Current Deferred Revenue Related Terms

Dannex Ayrton Starwin Current Deferred Revenue Historical Data

* Premium members only.

The historical data trend for Dannex Ayrton Starwin's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Dannex Ayrton Starwin Current Deferred Revenue Chart

Dannex Ayrton Starwin Annual Data
Trend
Current Deferred Revenue

Dannex Ayrton Starwin Semi-Annual Data
Current Deferred Revenue
XGHA:DASPHARMA
3GF Score
Dannex Ayrton Starwin PLC XGHA:DASPHARMA
Current Deferred Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Current Deferred Revenue of GHS0.00 Mil mean?
Dannex Ayrton Starwin (XGHA:DASPHARMA) has a Current Deferred Revenue of GHS0.00 Mil as of . 20. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Dannex Ayrton Starwin and its competitors.
Is Dannex Ayrton Starwin's Current Deferred Revenue too high?
Dannex Ayrton Starwin's current Current Deferred Revenue is GHS0.00 Mil. Overall, Dannex Ayrton Starwin has a GF Score™ of 3/100, reflecting its overall financial health beyond just this single metric.
How does Dannex Ayrton Starwin's Current Deferred Revenue compare to ?
Dannex Ayrton Starwin's Current Deferred Revenue of GHS0.00 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Deferred Revenue for a Drug Manufacturers company?
A good Current Deferred Revenue depends on the Drug Manufacturers industry context. However, Current Deferred Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Deferred Revenue mean?
A high Current Deferred Revenue can signal that a stock is expensive relative to its fundamentals. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Dannex Ayrton Starwin and its competitors. Dannex Ayrton Starwin's current Current Deferred Revenue is GHS0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dannex Ayrton Starwin stock overvalued right now?
Dannex Ayrton Starwin (XGHA:DASPHARMA) has a current Current Deferred Revenue of GHS0.00 Mil. The current Current Deferred Revenue is GHS0.00 Mil. Dannex Ayrton Starwin's overall GF Score™ is 3/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Deferred Revenue calculated?
Current Deferred Revenue is calculated from a company's financial statements. For Dannex Ayrton Starwin (XGHA:DASPHARMA), the current Current Deferred Revenue is GHS0.00 Mil as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Dannex Ayrton Starwin Business Description

Comparable Companies
Address No. 5 Dadeban Road, Ring Road North, North Industrial Area, Accra, GHA
Dannex Ayrton Starwin PLC is a pharmaceutical company. The company offers a product range that includes tablets, capsules, liquids syrups and suspensions, powders, ointments, and chemicals. It also manufactures and distributes Vitamin C.
3GF Score

Get the complete analysis for XGHA:DASPHARMA

Current Deferred Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

GHS1.64
Price